FDA Grants Accelerated Approval to Acalabrutinib for Mantle Cell Lymphoma
Oct 30
2017
The Food and Drug Administration granted accelerated approval to acalabrutinib (Calquence™, AstraZeneca Pharmaceuticals Inc. under license of Acerta Pharma BV) for treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
